Guidance under pressure, but order recovery and EUV inspection expansion improve the medium-term outlook

Overview

Lasertec is a supplier of photomask and related inspection and measurement systems, with semiconductor-related products accounting for about 90% of sales. FY6/26 results were broadly in line with expectations, but FY6/27 operating profit guidance was clearly below market consensus expectations. UBS believes margin pressure mainly stems from product mix changes and increased R&D and personnel investment, rather than a fundamental deterioration in product profitability. With a recovery in ACTIS and MATRICS orders and expanding EUV inspection demand, the company's second-half and medium-term growth outlook has improved.

Core views

The near-term focus is FY6/27 operating profit guidance falling short of expectations and a decline in operating margin, but the strong order outlook provides an important offset. AI-driven logic and memory investment, A200 HIT-driven fab deployment, demand for EUV thin-particle inspection, and adoption of curvilinear linear masks and EUV pellicles are all expected to become growth catalysts after the second half. Although the China market is subject to EUV export restrictions, DUV demand centered on MATRICS remains strong. UBS therefore raised its FY6/27 to FY6/29 earnings forecasts, but maintained a Neutral rating based on limited upside to the target price.

Analysis framework

The report compares actual results and company guidance with market consensus expectations, assesses earnings trends by considering order backlog, product demand, regional demand, and cost investment, and determines the 12-month target price using an EV/EBITDA method based on FY6/28 earnings forecasts.

Methodology notes

• Valuation methodsEV/EBITDA Valuation Method

  Enterprise value multiple valuation

  Based on FY6/28 earnings forecasts, the report applies a 22x EV/EBITDA valuation, down from the previous 25x; this multiple corresponds to an expected 35% YoY sales growth rate in FY6/28.

• Earnings AnalysisComparison of Actual Results and Consensus Expectations

  Expectation gap analysis

  The report compares FY6/26 actual results and FY6/27 company guidance with market consensus expectations, and assesses near-term pressure and medium-term growth potential by considering orders and product mix.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Lasertec Corporation (6920.T)

  Directly covered stock

  Strengths

  The company has core applied optical technologies in the mask and related inspection equipment field; it benefits from expanding EUV adoption, growth in AI-related logic and memory investment, and recovery in ACTIS and MATRICS orders.

  Weaknesses

  FY6/27 profit guidance is below market expectations, and product mix changes plus increased R&D and personnel investment will weigh on operating margin.

  Comparison

  FY6/27 sales guidance is only slightly below consensus expectations, but operating profit guidance shows a large gap versus consensus; meanwhile, order growth and earnings forecasts after FY6/28 have improved significantly.

  Risks

  Entry of competitors into the AMPI market, major customers adjusting investment plans, delays in ACTIS sales recognition, and fluctuations in semiconductor capital expenditure.

Key data

• FY6/26 sales¥230.5bn, YoY -8.3%Broadly in line with market consensus expectations.
• FY6/26 operating profit¥105.2bn, YoY -14.3%Slightly below the ¥106.2bn consensus expectation.
• Ending order backlog¥322.9bnUp ¥7bn from the beginning of the fiscal year, mainly driven by ACTIS and MATRICS.
• FY6/27 company sales guidance¥290bn, YoY +26%Slightly below the ¥292.8bn consensus expectation.
• FY6/27 company operating profit guidance¥125bnBelow the ¥139.6bn consensus expectation.
• FY6/27 order outlook¥300–400bn, midpoint ¥350bnManagement expects orders to achieve strong growth.
• UBS operating profit forecastsFY6/27 ¥137bn; FY6/28 ¥186.7bn; FY6/29 ¥219bnPrevious forecasts were ¥134.7bn, ¥162.6bn, and ¥191bn, respectively.
• Target price¥47,200Previously ¥46,600; potential upside of approximately 8.9% versus the 2026-08-06 closing price.

Impact & implications

FY6/27 profit guidance below expectations may limit near-term valuation expansion, but order backlog, the order growth outlook, and structural growth in EUV inspection demand improve earnings visibility after FY6/28. The target price increase reflects improved medium- to long-term earnings forecasts, while the valuation multiple reduction from 25x to 22x and the Neutral rating reflect near-term margin pressure and limited current upside.

Risks

• Competitors entering the AMPI market, weakening the company's market position or pricing power.
• Major customers reviewing or delaying capital expenditure plans, leading to lower equipment demand.
• Delays in ACTIS sales recognition, pushing back the timing of revenue and profit realization.
• Product mix changes and increased R&D and personnel investment putting pressure on FY6/27 operating margin.
• China EUV export restrictions may constrain some high-end equipment demand.

What to watch

• Whether FY6/27 orders can reach management's guidance range of ¥300–400bn.
• Whether the recovery in ACTIS and MATRICS orders can smoothly translate into revenue and profit.
• Whether A200 HIT can accelerate fab deployment in the second half.
• The pace of growth in demand for EUV thin-particle inspection, curvilinear linear masks, and EUV pellicles.
• Whether DUV orders centered on MATRICS in the China market can double.
• Whether progress in 2nm mass production and adoption of High-NA technology exceed expectations.
• The actual impact of R&D and personnel investment on FY6/27 margins.